658 filings
Page 7 of 33
6-K
onzcfzio
10 May 21
Immutep Operational Update
12:00am
6-K
dfw6piziwfeg2d40v
30 Apr 21
Immutep To Announce New TACTI-002 and INSIGHT-004 Data
12:00am
6-K
3wt0wi85es vvrp7upxr
19 Apr 21
Immutep Quarterly Activities Report & Appendix 4C
9:21pm
6-K
af935m9tty
19 Apr 21
Immutep receives A$1,155,055 R&D Tax Incentive
12:00am
6-K
c5s 7f6yh4
9 Apr 21
Immutep Achieves Fast Track Designation from Us Fda
12:00am
6-K
8gr elisd1
8 Apr 21
Immutep Announces European Patent Grant for LAG525 Antibody In Combination Therapy
12:00am
6-K
3p4 7ddx3
17 Mar 21
Current report (foreign)
12:00am
6-K
pgq2a8gwvr sf
10 Mar 21
Immutep Secures Second United States Patent Grant for Eftilagimod Alpha
12:00am
6-K
1rzl5rf aphtajdw2s9
5 Mar 21
Current report (foreign)
5:14pm
6-K
l8rlqo59jy0qinbafl
24 Feb 21
Half-Year Financial Report
12:00am
6-K
kuycx4zh2hgt
28 Jan 21
Immutep Announces Advancement of Phase Ii Trial for Eftilagimod Alpha In COVID-19 Patients to Randomised Portion of the Study
12:00am
6-K
kymawa2xqbkd4
25 Jan 21
Immutep Quarterly Activities Report & Appendix 4C
10:00am
6-K
onew qdimgo
8 Jan 21
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
12:00am
6-K
q4jtz62sgr8pea
31 Dec 20
Immutep Secures United States Patent for Eftilagimod Alpha
12:00am
6-K
jke397q
17 Dec 20
Current report (foreign)
12:00am
6-K
yk5pxlfhy8a94
16 Dec 20
Immutep Operational Update
12:00am
6-K
gfp429 esgp819n7dd7h
11 Dec 20
Immutep’s Chinese Partner EOC Pharma
12:00am
6-K
ub5t1h295rdod
11 Dec 20
Immutep Reports Statistically Significant Survival Benefit for Key
12:00am
6-K
f7q72uo xbnie
20 Nov 20
Immutep Announces Expansion of TACTI-002 Collaboration Trial
12:00am
6-K
oebx7
20 Nov 20
Immutep completes a A$29.6 million placement to accelerate and broaden its clinical development
12:00am